Latest Posted March 5, 2021

FTC Takes Further Action Against Deceptive CBD Claims

On March 5, 2021, the Federal Trade Commission (FTC) announced that it has approved final administrative consent orders against six companies for selling CBD products with unsupported and deceptive health claims that they can treat a variety of conditions, including cancer, heart disease, hypertension, Alzheimer's disease, and others. These companies are Bionatrol Health, LLC; Epichouse LLC (First Class Herbalist CBD); CBD Meds, Inc.; HempmeCBD; Reef Industries, Inc.; and Steves Distributing, LLC.

The FTC first took action in December of 2020, and a list of each company's products, unscientific claims, and FTC fines can be found here.

Consumers are encouraged to report scams, fraud, and bad business practices at ReportFraud.ftc.gov.

See ConsumerLab's Review of CBD & Hemp Extract Supplements, Lotions, and Balms for tests of related products.

For more information, use the link below.

FTC Approves Final Administrative Consent Orders against Sellers of Deceptively Marketed CBD Products

See related warnings:

FTC Crackdown on Six Deceptive CBD Products

FDA Warns Sellers of Unapproved COVID-19 Tests, CBD Products

Seller of CBD and NAC Warned for Coronavirus Claims

51 CBD Products Recalled Due to Lead Contamination

Seller of CBD Tinctures and "Immune Boost Packs" Warned for Coronavirus Claims